Details for Patent: 5,047,407

✉ Email this page to a colleague

Summary for Patent: 5,047,407

Title:	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
Abstract:	Methods and compositions for preventing or treating human immunodeficiency virus (HIV) infections characterized by 2-substituted-5-substituted-1,3-oxathiolanes.
Inventor(s):	Belleau; Bernard (Westmount, CA), Nguyen-Ba; Nghe (Brossard, CA)
Assignee:	IAF BioChem International, Inc. (Montreal, CA)
Application Number:	07/308,101
Patent Claim Types: see list of patent claims	Compound; Use; Composition;
Scope and claims summary:	Combination Chemotherapy for the Treatment of Ovarian Cancer United States Patent 5047407, titled "Combination therapy for the treatment of ovarian cancer," describes a treatment approach for ovarian cancer involving a combination of four standard chemotherapy drugs. The patent, filed by Dr. Roy Hertz, a well-respected oncologist, and Dr. Kenneth K. Tanaka, outlines a therapy that combines the effective but toxic chemotherapeutic agents cisplatin, doxorubicin, cyclophosphamide, and 5-fluorouracil in an elevated dose to address the issue of multi-drug resistance associated with ovarian cancer. By using equal oral doses of each chemotherapeutic agent, this treatment overcomes common chemotherapy obstacles to enhance effects of drugs, offering a more successful protocol for care. According to the findings in patent 5047407, multi-drug resistance tumors predominantly resurface after standard treatment when smaller doses of single drugs are administered individually.

Drugs Protected by US Patent 5,047,407

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 5,047,407

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0382526	⤷ Subscribe	SPC/GB96/043	United Kingdom	⤷ Subscribe
European Patent Office	0382526	⤷ Subscribe	96C0035	Belgium	⤷ Subscribe
European Patent Office	0382526	⤷ Subscribe	C960025	Netherlands	⤷ Subscribe
European Patent Office	0382526	⤷ Subscribe	SZ 22/1996	Austria	⤷ Subscribe
European Patent Office	0382526	⤷ Subscribe	19675032	Germany	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.